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Summary Purpose Population pharmacokinetics (PK) of
sepantronium bromide (YM155) was characterized in
patients with non-small cell lung cancer, hormone refractory
prostate cancer, or unresectable stage III or IV melanoma
and enrolled in one of three phase 2 studies conducted in
Europe or the U.S. Method Sepantronium was administered
as a continuous intravenous infusion (CIVI) at 4.8 mg/m2/
day over 7 days every 21 days. Population PK analysis was
performed using a linear one-compartment model involving
total body clearance (CL) and volume of distribution with
an inter-individual random effect on CL and a proportional
residual errors to describe 578 plasma sepantronium con-
centrations obtained from a total of 96 patients by NON-
MEM Version VI. The first-order conditional estimation
method with interaction was applied. Results The one-
compartment model with one random effect on CL and
two different proportional error models provided an ade-
quate description of the data. Creatinine clearance (CLCR),
cancer type, and alanine aminotransferase (ALT) were rec-
ognized as significant covariates of CL. CLCR was the most
influential covariate on sepantronium exposure and pre-
dicted to contribute to a 25 % decrease in CL for patients
with moderately impaired renal function (CLCR040 mL/
min) compared to patients with normal CLCR. Cancer type
and ALT had a smaller but nonetheless significant contribu-
tion. Other patient characteristics such as age, gender, and
race were not considered as significant covariates of CL.
Conclusions The results provide the important information
for optimizing the therapeutic efficacy and minimizing the
toxicity for sepantronium in cancer therapy.
Keywords Sepantronium bromide . YM155 . Population
pharmacokinetics . Non-small cell lung cancer . Hormone
refractory prostate cancer . Unresectable stage III or IV
melanoma
Introduction
Survivin is an apoptosis protein that has been implicated in
both cell survival and the regulation of mitosis in cancer [1].
While undetectable in most normal, differentiated tissues
with the exception of the placenta, testes, and rapidly divid-
ing cells such as CD34+ [1–5], survivin is highly expressed
in most human malignancies, including lung, melanoma,
breast, and aggressive non-Hodgkin lymphoma (NHL).
Studies have reported that the suppression of survivin indu-
ces tumor cell apoptosis, and also enhances sensitivity to
apoptosis induced by existing anti-cancer drugs and other
apoptosis stimuli [2], making it a potential target for cancer
therapy. Although relationship between the suppression of
survivin and tumor cell apoptosis has been well investigat-
ed, its mechanism of action remain unclear.
Sepantronium bromide (YM155, 1-(2-methoxyethyl)-2-
methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-
naphtho[2,3-d]imidazolium bromide, abbreviated as sepan-
tronium) is a small molecule survivin suppressant that was
identified by cell-based high-throughput screening and lead
optimization. Sepantronium selectively suppresses survivin
expression to cause activation of caspases and apoptosis
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induction in hormone refractory prostate cancer cells and
has been shown to have broad antitumor activity and induce
tumor regressions in various xenograft models [6–9]. Fur-
thermore, a time-dependent enhancement of anti-tumor ac-
tivity of sepantronium was suggested via continuous
infusion [8].
Phase 1 study was conducted to evaluate safety, tolera-
bility, efficacy and pharmacokinetics (PK) of sepantronium
as mono-therapy enrolling patients with advanced solid
tumors or NHL [10]. Phase 2 studies were conducted to
evaluate the safety, efficacy and PK of sepantronium as
mono-therapy in patients with non-small cell lung cancer
(NSCLC), hormone refractory prostate cancer (HRPC), or
unresectable stage III or IV melanoma (MM) with modest
single-agent activity [11–13]. Phase 2 studies with combi-
nation therapy have also been conducted in patients diag-
nosed with various types of solid tumors [14–16].
PK profile of sepantronium was evaluated in the phase 1
study by non-compartment model analysis. Mean values for
the elimination half-life, the total body clearance (CL), and
the distribution volume (V) of sepantronium at 4.8 mg/m2/
day are 26.3 h, 47.7 L/h, and 1763 L, respectively, and the
urinary excretion ratio of unchanged drug ranged from
18.3 % to 28.6 % of the dose [10].
The phase 1 study showed that Sepantronium was gen-
erally well tolerated, with a maximum tolerable dose (MTD)
of 4.8 mg/m2/day when administered as continuous intrave-
nous infusion (CIVI) for 7 days every 21 days. On the other
hand, reversible elevation in serum creatinine was found as
a dose limiting toxicity (DLT). One previous non-clinical
toxicology study found that short-term exposure at high
plasma concentrations causes nephrotoxicity [17]. The
DLT is consistent to the nephrotoxicity observed in non-
clinical toxicology study, and it is suggesting effective
sepantronium therapy depends on an appropriate concentra-
tion window. However, little is known about which factors
affect the PK of sepantronium.
Here, we characterize the effect of covariates on PK of
sepantronium and evaluate the extent of covariate effect
following the administration as CIVI for 7 days (168 h)
using a population PK model approach by analyzing data
from 3 different phase 2 studies in sepantronium mono-
therapy that enrolled patients with NSCLC, HRPC, or MM.
Methods
Study design
The population PK database was comprised of data from
three open-label, multi-center, phase 2 studies [11–13].
These phase 2 studies involved CIVI of sepantronium for
7 days (168 h) at 4.8 mg/m2/day every 21 days in patients
with NSCLC (33 patients), HRPC (34 patients), or MM (29
patients), ranging in age from 29 to 90 years. Patients in the
NSCLC study were enrolled in Europe, while those for the
other two studies came from North America. Sepantronium
was prepared for administration by diluting an appropriate
volume of concentrated stock solution in 5 % dextrose in a
light- and temperature-controlled environment. The first
sepantronium dose was calculated using actual body surface
area (BSA). One cycle was composed of a 7-day (168-h)
administration period and a 14-day observation period (1
cycle). Doses were expressed as those of the cationic moiety
of sepantronium bromide.
These studies were approved by an Ethics Committee or
Institutional Review Board and were conducted in accor-
dance with the current revision of the Declaration of
Helsinki.
Pharmacokinetic sampling
PK blood samples (6 mL/tube) were collected in sodium
heparin tubes. Samples were drawn during a 7-day (168-h)
CIVI, at immediately before stop of the CIVI, and 0.5–4 and
6–24 h after stop of the CIVI on cycle 1, and during a 7-day
CIVI on other cycles. A total of 578 PK blood samples were
obtained from 96 patients.
Bioanalytical procedures
Plasma concentrations of sepantronium were assayed using
a slightly modified version of a previously reported validat-
ed liquid chromatography tandem mass spectrometry (LC-
MS/MS) method [10]. The bioanalysis was performed at
PPD Central Laboratory (Richmond, VA, USA). The lower
limit of quantitation was 0.05 ng/mL in plasma. Concen-
trations were expressed as those of the cationic moiety of
sepantronium bromide. The plasma sepantronium assay was
linear at least 0.05 ng/mL and had excellent inter-day pre-
cision (<18.5 % for 0.05–40.0 ng/mL sepantronium), accu-
racy (<7.46 % deviation from nominal concentration), and
recovery (84.2 %–86.0 % for 0.15–40.0 ng/mL). No com-
pounds were seen to interfere with the sepantronium assay.
Data analysis
The population PK analysis was performed via nonlinear
mixed-effect modeling with the NONMEM software, Ver-
sion VI (ICON Development Solutions, Ellicott City, MD,
USA) [18]. PDX-Pop Version 3.0 (ICON) was used to track
all code patches/options. The first-order conditional estima-
tion method with interaction option (FOCEI) in NONMEM
was employed for all model runs. Plasma sepantronium
concentrations that were below the lower limit of
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quantitation (0.05 ng/mL) or missing values were excluded
from the analysis.
The final model selection was performed using various
diagnostic indicators including comparisons based on the
minimum objective function value (OFV), visual inspection
of goodness-of-fit plots, and estimation errors for population
fixed and random effect parameters. The population PK was
developed in a series of steps as follows: i) base model
development, ii) covariate model development, and iii)
model validation.
A one-compartment model was applied to describe the
plasma sepantronium concentration-versus-time profiles.
The structural PK model was parameterized in terms of
CL and V, as implemented using NONMEM with the
ADVAN1 and TRANS2 subroutines. All inter-individual
random effects were modeled exponentially (Eq. 1). An
attempt was made to define a full block covariance matrix
for the inter-individual random effects (Ω) when possible. A
graphical assessment of goodness-of-fit plots was conducted
to confirm the adequacy of the base model.
Pi ¼ Ppop  exp ηPið Þ ð1Þ
In Eq. 1, Pi is the parameter value for an individual i, Ppop
is the typical population value of the parameter, and ηPi is
individual-specific inter-individual random effect for param-
eter P of individual i, which are assumed to be distributed as
η~N(0, ω2).
For PK observations in this analysis, a residual error model
was initially described by a proportional error model (Eq. 2).
Cobs;ij ¼ Cpred;ij  1þ "ij
  ð2Þ
In Eq. 2, Cobs,ij is the j-th measured observation of indi-
vidual i, Cpred,ij is the j-th model predicted value of individ-
ual i, εij is a random effect for measurement j of individual i
and, respectively, and are each assumed to be independently
distributed as ε~N(0, σ2).
Covariate model
Individual empirical Bayesian (post-hoc) estimates of CL
were obtained from the base model. Symmetry in the dis-
tributions of the post-hoc estimates of ηCL were assessed
graphically. Effects of covariates on CL were typically mod-
eled using the following equations for continuous and bina-
ry variables, respectively.
CLpopjX¼Xj ¼ CLpopjX¼Xpop  Xj=Xpop
 θpower ð3Þ
CLpopjZ¼Zj ¼ CLpopjZ¼0  θratio;Zj ð4Þ
In Eqs. 3 and 4, Xj and Zj are the continuous and indica-
tor variables for the j-th subject, respectively, and θpower or
θratio are the fixed effect parameters. Xpop is a representative
value of X in the population, which is a median or an
arbitrary value close to the median. Zj has a value of 1 when
the j-th subject belongs to the category, otherwise it is 0.
When a model contains multiple continuous and discrete
covariates, the additional multiple factors were given in the
forms of Eqs. 3 or 4, respectively.
The covariate exploration was performed by taking
the following steps: First, a graphical assessment along
with a linear regression test or t-test was made for
screening out covariates that clearly did not exhibit
any trends. In the second step, the screened covariates
were subjected to a forward addition algorithm. Inclu-
sion was determined based on the results of a likelihood
ratio test with a significance level of 0.05 or better. In
the final step, a backward elimination, where an exclu-
sion of each covariate one at a time from the full model
in the step 2, was examined by likelihood ratio test with
a significance level of 0.01 or better to obtain the final
model.
Covariates investigated using this analysis included, cy-
cle, age, sex, race, alanine aminotransferase (ALT), aspartate
aminotransferase (AST), serum creatinine, creatinine clear-
ance (CLCR), measured body size (body weight [BW], BSA,
and height), albumin, α1-acid glycoprotein (α1-AGP), can-
cer type (study), and the Eastern Cooperative Oncology
Group (ECOG) performance status [19] on CL. CLCR was
estimated from serum creatinine concentration, age and BW
using the Cockcroft-Gault equation [20] shown in Eq. 5 and
estimated values were used directly for the analysis.
CLCR mL=minð Þ
¼ 140 Age yearsð Þ½   BW kgð Þ½ f g= 72 creatinine mg=dLð Þ½ 
0:85 if femaleð Þg
ð5Þ
Besides the above exploration processes, possible cova-
riates were chosen with considering scientific interest,
mechanistic plausibility, and prior knowledge to avoid un-
stableness of modeling due to correlation or co-linearity.
Model validation
The reliability of the final model and parameter esti-
mates were investigated by a nonparametric bootstrap
procedure [21, 22]. A total of 300 replicate data sets
were generated by random sampling with replacement.
Population parameters for each data set were subse-
quently estimated. Empirical 95 % CIs were constructed
by the 2.5th and 97.5th quartiles of population param-
eter estimates for each bootstrap runs with successful
convergence.
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Exposure parameter
Steady-state plasma sepantronium concentration during
CIVI (CSS) was calculated as a representative individual
exposure parameter from following equation:
CSS ng=mLð Þ
¼ Dose mgð Þ= CL L=hð Þ  CIVI duration hð Þ½ 
 1000 ð6Þ
In Eq. 6, dose is individual actual dose and CL is indi-
vidual post-hoc clearance from the final model.
Results
Analytical population and data characteristics
The analysis database was comprised of 96 patients (17
females and 79 males) contributing a total of 578 plasma
sepantronium concentrations (Table 1).
Patient demographics at screening are presented in
Table 2. For most patient characteristics except for α1-AGP
and AST, there is no statistically significant difference among
cancer types (P>0.05 for age, height, serum creatinine level
and CLCR, and P>0.01 for others). Median values of α1-AGP
in patients with MM (22 μmol/L) were lower than those in
patients with NSCLC or HRPC (35 μmol/L in both). Median
values of AST in HRPC (34 U/L) were higher than in other
cancer (21 U/L in NSCLC and 24 U/L in MM). All HRPC
patients were male and all NSCLC patients were Caucasian.
ECOG performance status was Grade 0 or 1 in MM, while
Grade 0, 1 or 2 in NSCLC and HRPC.
The plasma sepantronium concentration versus time pro-
file is presented in Fig. 1. Plasma sepantronium concentra-
tions were obtained at various times over a 7-day (168-h)
CIVI period and over 24 h after the end of the CIVI. Some
patients showed significant fluctuations in their plasma
sepantronium concentrations during CIVI (Fig. 1). Since it
was deemed difficult to correctly identify possible outliers
with the sparse data by visual inspection or available clinical
records, it was decided that no data were to be removed
from the analysis data set as outliers. Instead, a separate
residual error (intra-individual variability) model with a
different magnitude was set for the patients who had possi-
ble outliers to allow larger residual errors. Possible outliers
were then identified as follows:
Low outlier : less than Q1 3 IQR ð7Þ
High outlier : more than Q3þ 3 IQR ð8Þ
In Eqs. 7 and 8, Q1 and Q3 are the 1st and 3rd quartiles
of plasma sepantronium concentrations taken during CIVI
and IQR is the inter-quartile range of the plasma sepantro-
nium concentrations during CIVI, i.e. Q3-Q1. In total, 11
patients with 16 plasma sepantronium concentrations that
exceeded 23.13 ng/mL were identified as high outliers,
while no concentrations were identified as low outliers.
Population PK modeling
Population PK parameters derived from the base model are
shown in Table 3. After evaluating various base models,
inter-individual variability was assumed only in CL. The
base model, i.e. one-compartment model with one random
effect on CL and two different proportional error models
based on having possible outliers, provided an adequate
description of the data (Table 3).
As a result of the preliminary screening by linear regres-
sions and one-way ANOVA, age, α1-AGP, albumin, ALT,
body surface area, BW, CLCR, serum creatinine, cancer
type, and ECOG performance status were selected as poten-
tial covariates. The covariate exploration in the forward
addition step revealed CLCR, cancer type and ALT are the
potential covariates on CL. CLCR was found to be the most
influential as the addition of CLCR caused a decrease in
OFV of over −31 points. Cancer type and ALT had also a
significant effect on CL (a decrease in OFV was −19 and −8,
respectively). As the final step, the three potential covariates
were tested using the backward elimination algorithm. As a
result, the significance of all the covariates was confirmed.
Based on the final model including the fixed effects of
CLCR, cancer type, and ALT, individual CL (CLj) was
expressed as follows:
CLj ¼ 42:1 CLCR;j=79:22
 0:425
 ALTj=19:0
 0:124  0:955ðifHRPCÞ
 1:24ðifMMÞ ð9Þ
The parameter estimates of the final population PK mod-
el are also shown in Table 3. The final model resulted in an













NSCLC 33 191 5.8
HRPC 34 223 6.6
MM 29 164 5.7
Total 96 578 6.0
NSCLC, non-small cell lung cancer; HRPC hormone refractory pros-
tate cancer; MM unresectable melanoma
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improvement in the goodness-of-fit criteria, compared with the
base model. The estimation errors of the estimates were
adequately low in general. The inter-individual variances for
CL was 0.0385 (percentage coefficient of variation [CV%],
19.6 %) in the final model. The inter-individual variability for
CL was reduced in the final model, when compared with the
base model (28.9 %, 0.0838 in variance) variance estimate
(Table 3). Figure 2 shows a diagnostic plot of the final PK
model. The weighted residuals (WRES) over PRED andTIME
were distributed around 0, suggesting no systematic bias in the
model fitting. Plots of individual post-hoc estimates from the
final model versus the significant covariates revealed no
remaining trends. Distributions of inter-individual random
effects are centered at the expected value of zero, as indicated
by the eta-bar estimates included in the NONMEM output
(data not shown).
The final model was used to simulate CSS of sepantronium.
The magnitude of the covariate effects of CLCR on CL was
predicted to contribute a 25 % decrease in CL, which would
consequently lead to a 34 % increase in CSS in patients with
moderate impaired renal function (CLCR 040 mL/min).
Table 2 Characteristics of
patients included in the popula-
tion PK analysis (N096)
BSA Body surface area ; α1-AGP
α1-acid glycoprotein; ALT ala-
nine aminotransferase; AST as-
partate aminotransferase; CLCR
creatinine clearance; NSCLC
non-small cell lung cancer;
HRPC hormone refractory pros-
tate cancer; MM unresectable
melanoma
Median Mean Standard Deviation Min Max
Age, years 64 63 11.7 29 90
Body weight, kg 81 82 14.3 50 114
Height, m 1.76 1.74 0.08 1.53 1.92
BSA, m2 1.97 1.97 0.19 1.48 2.40
Albumin, g/L 38 37 4.8 22 45
α1-AGP, μmol/L 31 33 13.8 13 91
ALT, U/L 20 27 25.0 6 185
AST, U/L 25 30 16.3 12 92
Serum creatinine, μmol/L 88 91 23.1 53 180










African American 4 4.2
Caucasian 44 45.8
Caucasian, Hispanic or Latino 8 8.3
Caucasian, Non Hispanic or Latino 40 41.7
ECOG performance status
Grade 0 38 39.6
Grade 1 53 55.2
Grade 2 5 5.2
(a) normal scale (b) semi-log scale
Fig. 1 Plasma Sepantronium Concentration-Time Profiles. Line sequen-
tial observations taken in cycle 1, open circle observations in the other
cycles
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Model validation
The final model was subjected to a bootstrap analysis.
A total of 299 of 300 runs were successfully minimized.
The bootstrap means and confidence intervals from
299 successful runs out of 300 were well consistent
with the parameter estimates of the final model as
shown in Table 4, which indicates robustness of the
final model.
Exposure—safety relationship
Relationship between simulated CSS and treatment related
cardiac and renal adverse event was presented in Fig. 3.
Table 3 Population pharmaco-
kinetic model parameter
CV coefficient of variation;
CLCR creatinine clearance;
HRPC hormone refractory pros-
tate cancer; MM unresectable
melanoma; ALT alanine amino-
transferase; OFV objective func-
tion value
Parameter Final Model Base Model
Estimate Error (CV%) Estimate Error (CV%)
Structural PK CL (L/h) 42.1 4.9 45.6 3.3
V (L) 319 8.7 317 9.0
Fixed effect on CL CLCR (power) 0.425 14.5 NA
HRPC (ratio) 0.955 6.2 NA
MM (ratio) 1.24 6.3 NA
ALT (power) 0.124 32.2 NA
Random effect on CL 0.0385 16.0 0.0838 17.3
Random effect on w/o outliers 0.0934 10.2 0.0934 10.2
Cp (Residual error) with outliers 31.6 33.9 28.6 42.0
OFV 1985.227 2043.738
(a) OBS. vs. IPRED (b) WRES vs. PRED
(c) WRES vs. TIME (d) post-hoc eta (CL)
Fig. 2 Diagnostic Plots (Final Model). Open circle; non-small cell lung cancer, open square; hormone refractory prostate cancer, open triangle;
unresectable stage III or IV melanoma
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There was no obvious relationship between CSS and these
adverse events.
Discussion
We present here a population PK modeling of sepantronium
based on 578 samples obtained during CIVI or up to 24 h after
stop of CIVI from a total of 96 cancer patients suffering from
various types of advanced solid tumors. Dose regimens were
CIVI for 7 days at 4.8 mg/m2/day. The final model provided
population mean estimates of 42.1 L/h and 319 L for CL and
V, respectively. The estimate of CL was in line with the
previous results of 27.6–47.7 L/h obtained by phase 1 study
carried out in advanced solid tumors or NHL patients [10].
In a preliminary investigation, it was suggested that indi-
vidual Bayes estimates were strongly dependent on whether
or not patients had any measurable plasma concentration
data after end of infusion when a two-compartment model
was applied (data not shown). The individual Bayes esti-
mate of V still showed a weak relationship with elapsed time
after end of infusion of the last measurable concentration
data in cycle 1 even when a one-compartment model was
applied, suggesting the difficulty in separately estimating
the inter-patient variability in V from that in CL. To focus on
estimating reliable individual exposure parameter especially
during infusion, a simple one-compartment model was chosen
as a basic PK model. Nevertheless, the use of fixed Venabled
us to model the data and obtain good estimates for CL, which
is valuable in the regulation of sepantronium therapy.
In a few patients, fluctuations with very high CSS were
observed during CIVI and concentrations could vary more
than 50-fold from one value to another during CIVI, where
almost flat CSS-time profile was expected theoretically
(Fig. 1). Indeed, on further analysis, 16 plasma sepantro-
nium concentrations obtained from 11 out of 96 patients
Table 4 Bootstrap estimates of
final model
CI confidence interval; CLCR
creatinine clearance; HRPC hor-
mone refractory prostate cancer;
MM unresectable melanoma;
ALT alanine aminotransferase
Parameter Bootstrap (n0299) Final Model
estimate 95 % CI estimate 95 % CI
Structural PK CL (L/h) 42.1 38.2–46.6 42.1 38.1–46.1
V (L) 320 268–379 319 265–373
Fixed effect on CL CLCR (power) 0.424 0.306–0.524 0.425 0.304–0.546
HRPC (ratio) 0.958 0.825–1.08 0.955 0.838–1.07
MM (ratio) 1.24 1.10–1.41 1.24 1.09–1.39
ALT (power) 0.125 0.042–0.218 0.124 0.046–0.202
Random effect on CL 0.036 0.025–0.047 0.0385 0.026–0.051
Random effect on w/o outliers 0.092 0.076–0.111 0.0934 0.075–0.112











Treatment Related Cardiac and Renal Adverse Event
Grade 1 Grade 2 Grade 3 None
Fig. 3 Relationship between
steady state concentration of
YM155 and treatment related
cardiac and renal adverse event.
Grade 1, n04: Grade 2, n03:
Grade 3, n01: None, patients
without treatment related
cardiac or renal adverse event,
n088. Star represents a mean
value: box represents a range of
50% interval: a bar in each box
represents a median value: bar
under the box represents a 25
percentile: bar over the box
represents a 75 percentile: fixed
circle represents outlier
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were extracted as outliers. One of possible reasons was
accidental contamination at blood sampling or bioanalytical
procedure. However no errors implying such contamination
were found. Furthermore, these outliers could not be
explained by any patient characteristics or other factors, as
they were observed in all cancer types (n05 in NSCLC, n03
in HRPC, and n03 in MM) and all cycles in which blood
samples were obtained (cycles 1–6). Because this is the first
population PK analysis for sepantronium, it seemed inap-
propriate to exclude the high outliers without any firm
reasons. The final model with two different residual errors
reasonably handled the outliers and enabled to provide
reliable parameter estimates without data exclusions.
The covariate exploration suggests that CLCR, cancer
type and ALT were recognized as significant covariates of
sepantronium CL. As urinary excretion ratio of unchanged
drug is 18.3 %–28.6 % of the dose [10], therefore, renal
excretion is obviously one of major elimination routes for
sepantronium, it deemed quite reasonable that CLCR was
selected as the most influential covariate in the analysis.
Although ALT level was selected as a significant cova-
riate of CL in the analysis, the effect of ALT was expected
minimal effect on the CL of sepantronium because the
exponent of the fixed effect model for ALT (power func-
tions on CL) was close to 0 (i.e. 0.124). However, signifi-
cant increase in sepantronium exposure due to severe
hepatic impairment could not be fully ruled out because
the patient population in the analysis did not have evaluable
numbers of patients with high ALT beyond the upper limit
of normal (40 U/L). Further, the final model suggests that
patients with MM have slightly higher CL than those with
other solid tumors such as NCSLC or HRPC (Table 3).
However, because each study had patients with different
cancer type, it could not be concluded which factor has a
potential effect on CL, cancer type or differences in the
other conditions between studies. Inclusion of these factors
such as ALT and cancer type significantly improved the
population PK models based on the likelihood ratio test
and subsequently decreased the inter-individual variability
in CL of sepantronium: however, the clinical relevancy of
effects of cancer type and ALT on CL was thought to be
negligible at least among the patient populations studied.
Age, gender, and race were not selected as significant
covariates on CL of sepantronium in the analysis. We also
examined whether or not the concentrations of specific
proteins contributed to the variability in CL of sepantro-
nium, but did not detect any significant associations with
albumin or α1-AGP concentrations. These results are
consistent with a relatively low in vitro human plasma
protein binding ratio of sepantronium (18 %–20 %)
(unpublished data).
Previous non-clinical studies have found that sepantro-
nium exerts time-dependent antitumor activity with a
continuous infusion and that short-term exposure at high
plasma sepantronium concentrations can cause cardiac tox-
icity and nephrotoxicity [8, 17]. Although sepantronium is
generally safe at 7-day CIVI of 4.8 mg/m2/day as previously
reported [10–13, 17], it is anticipated that outrageously high
plasma concentration of sepantronium observed in these
studies could cause adverse event related to exposure de-
pendent cardiac and renal toxicity of sepantronium found in
non-clinical studies. Nine Grade 1 or more cardiac and renal
adverse events probably or possibly related to the study drug
were observed in 8 of 96 patients. There was no clear
relationship between CSS and these adverse events as shown
in Fig. 3. Grade 3 or 4 adverse events related to the study
drug recorded in 11 patients with providing transient high
plasma sepantronium concentrations (high outliers) were
grade 3 arrhythmia (n01), hypokalaemia (n01), muscle
weakness (n01), thrombocytopenia (n01), hyponatrae-
mia (n01), and grade 4 fatigue (n01). Grade 1 tachycardia
(n01) and grade 3 arrhythmia (n01) were recorded as cardiac
or renal adverse events related to the study drug in
patients with high CSS and/or outlier concentrations.
However, the high CSS or outliers seemed not to asso-
ciate with the cause of the events because these events
were also observed in patients who had lower CSS. The
fact suggests that therapeutic drug monitoring is not
necessary for safe use of sepantronium.
In conclusion, CLCR was the most influential covariate
on sepantronium exposure and predicted to contribute to a
25 % decrease in CL for patients with moderately impaired
renal function (CLCR040 mL/min) compared to patients
with normal CLCR, with cancer type and ALT having a
smaller but nonetheless significant contribution. Other pa-
tient characteristics such as age, gender, and race were not
considered as significant covariates of CL. The analysis
provides the important information for optimizing the ther-
apeutic efficacy and minimizing the toxicity for sepantro-
nium in cancer therapy.
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